Category: Pα+ - Psychedelic Alpha

Read more about the article Reunion Neuroscience Posts Strong Phase 2 Results for RE104 in Postpartum Depression

Reunion Neuroscience Posts Strong Phase 2 Results for RE104 in Postpartum Depression

Post published:August 18, 2025
Post category:Analysis News Pα+

Read more about the article One Year After FDA’s MDMA Rejection: Insiders and Observers Reflect

One Year After FDA’s MDMA Rejection: Insiders and Observers Reflect

Post published:August 15, 2025
Post category:Analysis Pα+

Read more about the article Pα+ Psychedelic Bulletin #206: Q2’25 Psychedelic Lobbying; Tabernanthalog’s Neuroplasticity Pathway; UK Moves to Ease Schedule I Research Restrictions

Pα+ Psychedelic Bulletin #206: Q2’25 Psychedelic Lobbying; Tabernanthalog’s Neuroplasticity Pathway; UK Moves to Ease Schedule I Research Restrictions

Post published:August 8, 2025
Post category:Psychedelic Bulletin Pα+

Read more about the article Therapy or Threat? UK Expert Warns of Rising Ketamine Addiction as Phase III Alcoholism Trial Launches

Therapy or Threat? UK Expert Warns of Rising Ketamine Addiction as Phase III Alcoholism Trial Launches

Post published:August 5, 2025
Post category:Analysis Interviews News Pα+

Read more about the article Pα+ Psychedelic Bulletin #205: AbbVie Eyes Gilgamesh; Psychedelics Use Increases in U.S.; FDA Moves to Ban Kraton Compound 7-OH; What Is Sinema Selling?

Pα+ Psychedelic Bulletin #205: AbbVie Eyes Gilgamesh; Psychedelics Use Increases in U.S.; FDA Moves to Ban Kraton Compound 7-OH; What Is Sinema Selling?

Post published:August 1, 2025
Post category:Psychedelic Bulletin Pα+

Read more about the article Pα+ Psychedelic Bulletin #204: FDA Keeps GH Research’s 5-MeO-DMT on Ice; Makary’s Priority Voucher Pilot Launches, Mentions Innovative PTSD Treatments; HALT Fentanyl Act Could Streamline Schedule I Research

Pα+ Psychedelic Bulletin #204: FDA Keeps GH Research’s 5-MeO-DMT on Ice; Makary’s Priority Voucher Pilot Launches, Mentions Innovative PTSD Treatments; HALT Fentanyl Act Could Streamline Schedule I Research

Post published:July 25, 2025
Post category:Psychedelic Bulletin Pα+

Read more about the article June 2025 Psychedelic Patent Update

June 2025 Psychedelic Patent Update

Post published:July 24, 2025
Post category:Psychedelic Patent Analysis Pα+

Read more about the article Dispatch: The Neurobiology of Psychedelics Gordon Research Conference — Plasticity, Psychotherapy, and Perception (Part 1)

Dispatch: The Neurobiology of Psychedelics Gordon Research Conference — Plasticity, Psychotherapy, and Perception (Part 1)

Post published:July 23, 2025
Post category:Analysis News Pα+

Read more about the article Pα+ Psychedelic Bulletin #203: Norway Considers Funding Off-Label Ketamine for TRD; Longevity Crowd Hypes Psilocybin Study; Will State-Legal Psychedelics Eat Psychedelic Pharma’s Lunch?

Pα+ Psychedelic Bulletin #203: Norway Considers Funding Off-Label Ketamine for TRD; Longevity Crowd Hypes Psilocybin Study; Will State-Legal Psychedelics Eat Psychedelic Pharma’s Lunch?

Post published:July 14, 2025
Post category:Psychedelic Bulletin Pα+

Read more about the article Psychedelic Funding Update: Q2 2025

Psychedelic Funding Update: Q2 2025

Post published:July 9, 2025
Post category:Analysis Pα+

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.